|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 142.50 GBX | 0.00% |
|
+0.71% | +11.33% |
| 06-02 | Diaceutics PLC, 2025 Earnings Call, May 26, 2026 | |
| 05-26 | Diaceutics PLC Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Business description: Diaceutics PLC
Number of employees: 205
Sales by Activity: Diaceutics PLC
| Fiscal Period: December | 2020 (GBP) | 2021 (GBP) | 2022 (GBP) | 2023 (GBP) | 2024 (GBP) |
|---|---|---|---|---|---|
Medical Labs & Research | 12.7M | 13.94M | 19.5M | 23.7M | 32.16M |
Geographical breakdown of sales: Diaceutics PLC
| Fiscal Period: December | 2020 (GBP) | 2021 (GBP) | 2022 (GBP) | 2023 (GBP) | 2024 (GBP) |
|---|---|---|---|---|---|
North America | - | 8.46M | 14.45M | 20.83M | 29.54M |
Europe | 4.24M | 3.62M | 2.7M | 2.47M | 1.89M |
UK | 543K | 555K | 561K | 352K | 547K |
Asia and Rest of World | - | 1.31M | 1.79M | 45K | 181K |
Asia | 1.88M | - | - | - | - |
USA | 6.04M | - | - | - | - |
Executive Committee: Diaceutics PLC
| Manager | Title | Age | Since |
|---|---|---|---|
Ryan Keeling
CEO | Chief Executive Officer | 42 | 2023-12-31 |
Nick Roberts
DFI | Director of Finance/CFO | - | 2022-03-17 |
Ken Ruppel
CTO | Chief Tech/Sci/R&D Officer | - | 2024-01-31 |
Gillian Shaw
CMP | Compliance Officer | - | 2022-03-31 |
Johnny Rice
CTO | Chief Tech/Sci/R&D Officer | - | 2018-01-31 |
Composition of the Board of Directors: Diaceutics PLC
| Director | Title | Age | Since |
|---|---|---|---|
Graham Paterson
BRD | Director/Board Member | 55 | 2023-09-30 |
Peter Keeling
CHM | Chairman | 65 | 2024-09-30 |
Ryan Keeling
BRD | Director/Board Member | 42 | - |
Jordan Clark
BRD | Director/Board Member | 42 | 2024-09-30 |
| Director/Board Member | 58 | 2024-10-28 | |
Nick Roberts
BRD | Director/Board Member | - | 2022-03-17 |
Company details: Diaceutics PLC
Group companies: Diaceutics PLC
| Name | Category and Sector |
|---|---|
Diaceutics Ireland Ltd.
 Diaceutics Ireland Ltd. Medical/Nursing ServicesHealth Services Provides diagnostic services |
Medical/Nursing Services
|
Diaceutics Ireland Ltd.
Diaceutics Ireland Ltd. Medical/Nursing ServicesHealth Services Provides diagnostic services |
Medical/Nursing Services
|
Data Processing Services
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +0.71% | +13.55% | +65.70% | 162M | |
| +11.93% | +14.16% | +451.81% | +1,273.13% | 59.49B | |
| +10.01% | +1.87% | +34.16% | +54.11% | 3.94B | |
| +3.73% | -11.68% | +31.20% | +95.00% | 3.28B | |
| +4.18% | -0.29% | -28.92% | +22.36% | 1.35B | |
| +0.87% | -1.88% | -20.29% | -57.83% | 1.3B | |
| +2.51% | +0.82% | +34.25% | +240.28% | 1.22B | |
| +0.69% | +1.07% | -28.58% | +35.72% | 1.13B | |
| +3.84% | -1.09% | -28.13% | -54.71% | 1.07B | |
| Average | +2.81% | -0.89% | +51.01% | +185.97% | 8.11B | |
| Weighted average by Cap. | +0.45% | +1.41% | +370.53% | +1,048.67% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DXRX Stock
- Company Diaceutics PLC
Select your edition
All financial news and data tailored to specific country editions
